What Happens to DHEA-S Levels in Perimenopause?

What Happens to DHEA-S Levels in Perimenopause?

DHEA-S levels decline steadily from your mid-20s onward, so by perimenopause most women have already lost 50–70% of their peak output — and that decline accelerates during the hormonal flux of the perimenopausal transition. The main caveat: the rate of decline varies widely between individuals, so some women feel the effects sharply in their 40s while others barely notice until later. Women with high chronic stress or poor sleep tend to drop faster, because cortisol competes with DHEA for the same adrenal precursor pool.

What Is DHEA-S and Why Does It Matter?

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated, storage form of DHEA — the most abundant circulating steroid hormone in the human body. It is synthesized almost exclusively in the adrenal cortex and serves as a precursor to both androgens (testosterone, DHT) and estrogens. Because it has a long half-life of 7–10 hours compared to free DHEA's 15–30 minutes, DHEA-S is the form measured on standard blood panels and is considered the most reliable index of adrenal androgen production.

At its peak (typically ages 20–25), serum DHEA-S runs between 200–350 µg/dL in most women. By the mid-40s — the window when perimenopause begins for many — levels commonly sit between 80–180 µg/dL. By menopause, they often fall below 100 µg/dL. Labrie and colleagues documented this age-related decline curve across more than 2,000 subjects, showing a roughly 2–3% annual loss that becomes clinically meaningful by the fifth decade (Labrie F et al., J Steroid Biochem Mol Biol 2003; PMID: 12948536).

This matters because DHEA-S is not merely a precursor — it has direct biological activity at GABA-A, sigma-1, and androgen receptors, and epidemiological data consistently link lower DHEA-S to worse cardiometabolic risk, reduced bone density, and lower quality-of-life scores in midlife women (Cappola AR et al., J Clin Endocrinol Metab 2009; PMID: 19470626). The same DHEA-S pool that feeds testosterone synthesis also influences what happens to testosterone in perimenopause, which is why these two markers tend to move together on a blood panel.

How Perimenopause Specifically Accelerates the Drop

The decline of DHEA-S is not caused by perimenopause per se — it is part of a process called adrenopause, which begins independently of ovarian aging. But the two processes overlap badly in the late 30s and 40s, and several perimenopausal mechanisms make things worse:

1. Rising cortisol variability. Estrogen has a buffering effect on the HPA axis. As estradiol fluctuates and then falls, cortisol reactivity increases. Because cortisol and DHEA-S share the same upstream precursor (pregnenolone), chronically elevated or dysregulated cortisol effectively steals from the DHEA-S pool — a phenomenon sometimes called "pregnenolone steal," though the term oversimplifies the enzymatic competition involved.

1. Reduced conversion efficiency. The enzyme CYP11A1 (side-chain cleavage) and CYP17A1 (17α-hydroxylase/lyase) govern the branch point between cortisol and DHEA synthesis. Aging adrenals show a progressive shift toward cortisol-biased enzyme activity, so even when pregnenolone supply is adequate, less of it is channeled into DHEA-S (Miller WL, Endocr Rev 2013; PMID: 23338745).

1. Reduced DHEA sulfotransferase (SULT2A1) activity. The conversion of free DHEA to its sulfated storage form also declines with age, meaning the bioavailable reservoir shrinks faster than adrenal output alone would predict.

1. Sleep architecture disruption. DHEA secretion follows a pulsatile pattern partially tied to slow-wave sleep. Perimenopause commonly fragments sleep — night sweats, cortisol spikes, insomnia — which reduces the overnight DHEA pulses that partially replenish daytime levels. This creates a feedback loop: low DHEA worsens sleep quality via reduced GABA-A modulation, and poor sleep further suppresses DHEA.

The net result is that a woman entering perimenopause with a DHEA-S already sitting at 130 µg/dL may see it fall to 70–90 µg/dL within three to five years — a drop that can precipitate noticeable symptoms even though no individual test result looks dramatically abnormal.

DHEA for Energy: What the Research Actually Shows

One of the most consistent complaints associated with falling DHEA-S is fatigue that does not resolve with adequate sleep. The mechanistic explanation involves two pathways: first, DHEA's role as a mitochondrial co-activator (it upregulates PGC-1α expression in animal models); second, its conversion to testosterone and estradiol, both of which independently support motivation, dopamine signaling, and physical stamina.

A randomized, double-blind, placebo-controlled trial published in the Journal of Clinical Endocrinology & Metabolism examined 280 older adults (mean age 70) given 50 mg/day oral DHEA or placebo for two years. While the primary endpoint was bone density, secondary outcomes included fatigue scores and physical function — both of which improved significantly in the DHEA group relative to placebo (Jankowski CM et al., J Clin Endocrinol Metab 2006; PMID: 16551737). Importantly, responders were those with the lowest baseline DHEA-S, reinforcing the principle that supplementing into an already-adequate range adds little.

A separate meta-analysis of 25 randomized controlled trials found that DHEA supplementation produced statistically significant improvements in well-being and fatigue in women — particularly those under age 60 — but effects were modest (pooled standardized mean difference ~0.3), suggesting DHEA is one lever among many rather than a standalone energy intervention (Peixoto C et al., Climacteric 2017; PMID: 28301216).

Practically, this means checking your DHEA-S level before assuming the fatigue is adrenal in origin. If your number is already mid-range for your age, supplementing is unlikely to move the needle on energy. If it is in the lower quartile — below 60–80 µg/dL for women in their late 40s — there is reasonable trial evidence to support a 25–50 mg supplementation protocol under medical supervision.

DHEA for Skin: Collagen, Sebum, and the Intracrine Model

Skin aging accelerates visibly during perimenopause, and declining DHEA-S is one of the underappreciated drivers. The skin is an intracrine organ: it expresses the full enzymatic machinery (3β-HSD, 17β-HSD, aromatase) needed to convert DHEA-S into active androgens and estrogens locally, without requiring systemic conversion. This local conversion drives sebum production, collagen synthesis, epidermal hydration, and wound healing.

Labrie's group demonstrated in a controlled trial that topical DHEA applied to the forearm significantly increased skin thickness, hydration, and sebum content in postmenopausal women over a 12-month period, with effects comparable to topical estrogen on hydration but with added androgenic benefits on sebum and papillary dermis collagen (Labrie F et al., Menopause 2009; PMID: 19131848). Oral systemic DHEA produces similar but more diffuse effects because the skin captures a fraction of circulating DHEA-S for local activation.

For perimenopausal women specifically, the skin changes often predate other hormonal symptoms because the skin's intracrine sensitivity to DHEA-S decline is high. Dryness, thinning, and loss of elasticity in the late 30s and early 40s — before periods become irregular — can be an early signal that the adrenal DHEA-S pool is already shrinking.

DHEA for Hair Growth: Androgens, Follicle Cycling, and the Scalp

Hair loss in perimenopause is a frequent complaint that intersects with what happens to estradiol in perimenopause and with DHEA-S decline simultaneously. The relationship is non-linear: hair follicles on the scalp respond to androgens differently depending on follicle location and genetic sensitivity. Frontal and vertex follicles are sensitive to DHT (converted from testosterone downstream of DHEA-S) and miniaturize under androgenic stimulation, while general diffuse thinning is more often related to low estrogen and low androgens across the board.

Perimenopausal hair loss is therefore often a mixed picture: some women see increased shedding from low overall androgens as DHEA-S falls, while women with androgenic alopecia susceptibility may paradoxically see worsening thinning if the DHEA-S-to-testosterone pathway is relatively preserved while estrogen drops.

A 2012 study of 30 women with female pattern hair loss found that serum DHEA-S was significantly lower in affected women compared to age-matched controls, suggesting that low adrenal androgen output — rather than excess androgen — was the primary driver in the majority of perimenopausal hair loss cases (Matilainen V et al., European Journal of Dermatology 2003; PMID: 12844374). This underscores the importance of actually measuring DHEA-S rather than guessing direction from symptoms.

Systemic DHEA supplementation at 25–50 mg/day has been shown to increase terminal hair counts in women with adrenal insufficiency, and smaller pilot trials in women with normal adrenal function but low-normal DHEA-S have shown modest benefit. The evidence is less robust here than for skin or energy, but the biological plausibility is solid given the follicle's androgen receptor expression and its dependence on locally converted DHEA metabolites.

How DHEA-S Interacts With Other Perimenopausal Hormones

DHEA-S does not exist in isolation. It is part of a hormonal network that shifts dramatically during the perimenopausal transition. Understanding the interactions matters for interpreting any single lab value:

• SHBG: As estrogen fluctuates, SHBG levels in perimenopause shift as well. Rising SHBG binds free testosterone (which is partly derived from DHEA-S), reducing bioavailable androgen even when total DHEA-S looks acceptable on paper.
• Thyroid function: Low DHEA-S is associated with impaired T4-to-T3 conversion in some studies, and thyroid dysfunction in turn affects adrenal output. Reviewing what happens to your thyroid in perimenopause alongside DHEA-S gives a more complete picture of why fatigue is so multifactorial in this life stage.
• Cortisol: As discussed above, elevated cortisol competes with DHEA synthesis at the pregnenolone branch point. Chronic psychological or physiological stress is therefore one of the modifiable factors that can be addressed even when DHEA supplementation is not appropriate.
• Insulin sensitivity: DHEA-S has insulin-sensitizing properties in adipose and muscle tissue. As levels fall, insulin resistance can worsen — contributing to the abdominal weight gain many perimenopausal women experience independently of caloric changes.

Who Declines the Fastest — and Who Is the Exception?

Not every perimenopausal woman experiences the same degree of DHEA-S loss. Several factors accelerate decline beyond the expected 2–3% per year:

• Chronic psychological stress (the single largest modifiable driver — cortisol chronically above 18–20 µg/dL morning levels correlates with lower DHEA-S independent of age)
• Nutritional deficiencies — particularly zinc, magnesium, and vitamin B5, which are cofactors in adrenal steroidogenesis
• Obesity — adipose tissue expresses enzymes that degrade DHEA to inactive metabolites, increasing clearance
• Autoimmune adrenal involvement — subclinical autoimmune activity can reduce zona reticularis function before full adrenal insufficiency is diagnosable
• History of oral contraceptive use — long-term OCP suppresses the HPG axis and some evidence suggests it also modestly reduces DHEA-S, though this normalizes after discontinuation in most women

The exceptions — women who maintain relatively robust DHEA-S into their late 40s — tend to share: regular resistance exercise (which acutely and chronically stimulates adrenal androgen output), lower chronic psychological stress burden, and adequate sleep. Genetic variation in CYP17A1 and SULT2A1 also explains some of the between-individual variability that lifestyle cannot fully account for.

What This Means for Your Formula

DHEA itself is a controlled or prescription substance in several countries, but the adrenal support strategy available through supplementation focuses on reducing the cortisol-DHEA competition and supporting the enzymatic machinery that governs adrenal output.

Ones addresses this through its Adrenal Support System Blend, which combines adaptogens and adrenal cofactors specifically targeted at the HPA axis. The blend includes Ashwagandha (KSM-66 at 600 mg) — the most studied adaptogen for cortisol reduction. A randomized, double-blind trial in 64 adults found KSM-66 reduced serum cortisol by 27.9% over 60 days versus placebo (Chandrasekhar K et al., Indian J Psychol Med 2012; PMID: 23439798), which directly reduces the pregnenolone-steal pressure on DHEA-S synthesis. By lowering morning and evening cortisol spikes, KSM-66 effectively opens more upstream precursor availability for the DHEA pathway.

Ones also includes Vitamin D3 + K2 (MK-7) at clinically meaningful doses. Vitamin D receptors are expressed in the adrenal cortex, and deficiency is independently associated with lower DHEA-S in observational studies — a relevant connection given how commonly vitamin D falls during perimenopause as well (see what happens to vitamin D in perimenopause). The K2 (MK-7) component supports calcium partitioning, which has downstream relevance to bone density — another marker under pressure as DHEA-S declines.

For women whose Ones AI analysis identifies both low DHEA-S markers and elevated cortisol patterns from wearable or blood data, the formula may include Rhodiola Rosea as a secondary adaptogen. Rhodiola's primary mechanism — inhibition of catechol-O-methyltransferase and monoamine oxidase — reduces the stress-driven cortisol spikes that compete with DHEA synthesis, while also improving energy and cognitive function independently.

No supplement replaces a formal DHEA prescription when levels are severely low, but the combination of cortisol management and adrenal cofactor support represents the evidence-based non-prescription approach to preserving your remaining DHEA-S output during the perimenopausal transition.

Key Takeaways

• DHEA-S peaks in your mid-20s and has already fallen 50–70% by the time perimenopause begins; the transition accelerates the decline through cortisol competition and sleep disruption.
• Falling DHEA-S contributes to fatigue, skin thinning, hair shedding, and insulin resistance — but it is not the only driver of any of these symptoms, so testing before supplementing matters.
• Oral DHEA supplementation (25–50 mg/day) shows the clearest benefit in women with low-normal or low baseline DHEA-S; effects in women with mid-range levels are minimal.
• Chronic stress is the largest modifiable accelerator of DHEA-S decline, operating through the cortisol-pregnenolone competition at the adrenal level.
• Skin and energy benefits from DHEA have the most robust trial evidence; hair growth evidence is mechanistically plausible but requires more controlled trial data.
• Supporting adrenal function through cortisol-lowering adaptogens (KSM-66 ashwagandha, Rhodiola) and micronutrient cofactors (Vitamin D3, zinc, B5) is the non-prescription strategy most supported by current evidence.